Today's Daily Dose brings you news about Oragenics' progress in its phase II oral mucositis trial; Nasdaq notification for Neovasc; approval of TiGenix and Takeda's Alofisel in Europe, and CHMP opinion on Portola's Betrixaban, and Clovis' Rubraca.
from RTT - Biotech https://ift.tt/2G8lwMN
via IFTTT
No comments:
Post a Comment